Cryo Check Factor XII Deficient Plasma Model FDP12-10 (1.0ml) and FDP12-15 (1.5ml)
by Precision Biologicals, Inc.
510(k) K981174
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK981174 | Date13 Jan 1999 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- GJT
- Device Class
- Class II
- Regulation
- 21 CFR Part 864.7290
- Advisory Committee
- Hematology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
This device is a Plasma, Coagulation Factor Deficient (per FDA nomenclature), specifically designed as a substrate for clot-based Factor XII assays. It is immunodepleted, platelet-poor human plasma with less than 1% residual Factor XII activity, verified through antigenic and functional assays. Other coagulation factors are assayed and documented per lot on the accompanying certificate of analysis.
The product is supplied as a frozen, single-use plasma sample in volumes of 1.0 mL (Model FDP12-10) and 1.5 mL (Model FDP12-15). It is intended for use in clinical laboratory settings to serve as a deficient substrate for Factor XII assays, with no regulatory status implied beyond the stated FDA 510K clearance (K981174) under the Hematology advisory committee. Storage and handling follow standard frozen plasma protocols.
Other devices from Precision Biologicals, Inc.
Questions
AI-generated answers, 19 Sep 2026
What is the primary use of the CRYO CHECK Factor XII Deficient Plasma in a clinical laboratory setting?
This plasma is specifically designed as a substrate for clot-based Factor XII assays, serving as a deficient control to validate test accuracy. It is immunodepleted and platelet-poor, with less than 1% residual Factor XII activity, ensuring reliable results when assessing Factor XII levels in patient samples.
Are the 1.0 mL (FDP12-10) and 1.5 mL (FDP12-15) models interchangeable in testing, or do they serve distinct purposes?
Both models are single-use plasma samples with identical composition and intended use, differing only in volume. The choice between them depends on laboratory workflow and sample requirements—1.0 mL for smaller assays or limited testing, and 1.5 mL for larger batches or repeated testing.
How should the plasma be stored and prepared for use, given it is supplied frozen?
The plasma must be stored frozen according to standard frozen plasma protocols to maintain integrity. Thawing should be done slowly at 37°C (or per manufacturer guidelines) and used immediately after thawing, as it is a single-use product. Avoid repeated freeze-thaw cycles to preserve its deficient Factor XII characteristics.
Does this product require any special handling or validation beyond standard plasma storage, given its low residual Factor XII activity?
Beyond standard frozen plasma storage, no additional handling is required. Each lot includes a certificate of analysis documenting residual Factor XII activity (<1%) and levels of other coagulation factors, ensuring traceability and validation for assay calibration. Always verify the COA before use.